Submission of the manuscript is online via e-mail
ecgarticle@gmail.com or
cholerez@mail.ru

Tel: +7 903 250 5288

Editorial Correspondence e-mail
gastrossr@gmail.com


Publishing, Subscriptions, Sales and Advertising, Correspondence e-mail
journal@cniig.ru

Tel: +7 917 561 9505

SCImago Journal & Country Rank

    1. Federal state budget scientific institution «Federal research centre “of the Krasnoyarsk scientific center of the Siberian branch of the Russian Academy of Sciences”» (Krasnoyarsk, Russian Federation)

    Keywords: microbiome, microflora, stomach, H. pylori, pathology

    Abstract: The publication in 1984 in the Lancet of Australian authors R. Warren and B. Marshall about the discovery Helicobacter pylori was the first stage of revolutionary changes of views on the development of gastric pathology. Beginning the 21st century was marked by the proof of the existence in the stomach of a large number of other microorganisms. The second stage of the revolution was verified by the Kyoto consensus about gastritis and European Maastricht 5 consensus, confirmed the possibility of vital activity and association with gastric pathology of various bacteria, viruses and fungi.

      1. Marshall B.J., Warren J.R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1(8390):1311–1315.
      2. Kazor C.E., Mitchell P.M., Lee A.M., Stokes L.N., Dewhirst F.E., Paster B.J. Diversity of bacterial populations on the tongue dorsa of patients with halitosis and healthy patients. Journal of Clinical Microbiology. 2003;41(2):558–563.
      3. Fraher M.H., O’Toole P.W., Quigley E.M. Techniques used to characterize the gut microbiota: a guide for the clinician. Nature Reviews Gastroenterology & Hepatology. 2012;9(6):312–322.
      4. Bik E.M., Eckburg P.B., Gill S.R., Nelson K.E., Purdom E.A., Francois F., Perez-Perez G., Blaser M.J., Relman D.A. Molecular analysis of the bacterial microbiota in the human stomach. Proc. Natl. Acad. Sci. USA. 2006;103(3):732–737.
      5. . Li X.X., Wong G.L., To K.F, Wong V.W.-S., Lai L.H., Chow D.K.L., Lau J.Y.-W., Sung J.-Y., Ding C. Bacterial microbiota profiling in gastritis without Helicobacter pylori infection or non-steroidal anti-inflammatory drug use. PLoS One. 2009;4(11):e7985.
      6. Engstrand L., Lindberg M. Helicobacter pylori and the gastric microbiota. Best Practice & Research Clinical Gastroenterology. 2013;27(1):39-45.
      7. Delgado S., Cabrera-Rubio R., Mira A., Suárez A., Mayo B. Microbiological survey of the human gastric ecosystem using culturing and pyrosequencing methods. Microbial Ecology. 2013;65(3):763–772.
      8. Cao L., Yu J. Effect of Helicobacter pylori Infection on the Composition of Gastric Microbiota in the Development of Gastric Cancer. Gastrointestinal Tumors. 2015;2(1):14–25.
      9. Tan M.P., Kaparakis M., Galic M., Pedersen J., Pearse M., Wijburg O.L.C., Janssen P.H., Strugnell R.A. Chronic Helicobacter pylori infection does not significantly alter the microbiota of the murine stomach. Appl. Environ. Microbiol. 2007;73(3):1010–1013.
      10. Khosravi Y., Dieye Y., Poh B.H., Ng C.G.,Loke M.F., Goh K.L.,Vadivelu J. Culturable bacterial microbiota of the stomach of Helicobacter pylori positive and negative gastric disease patients. Scientific World Journal. 2014;2014:610421.
      11. Sheh A., Fox J.G. The role of the gastrointestinal microbiome in Helicobacter pylori pathogenesis. Gut Microbes. 2013;4(6):505–531.
      12. Iizasa H., Ishihara S., Richardo T., Timmy Richardo T., Kanehiro Y., Yoshiyama H. Dysbiotic infection in the stomach. World Journal of Gastroenterology. 2015;21(40):11450–11457.
      13. Butorin N.N., Bichurina T.B., Tsukanov V.V., Kasparov E.V., Kuklin D.V., Timoshenko V.O., Shtygasheva O.V., Maady A.S., Vasyutin A.V. Rasprostranennost' i klinicheskie aspekty pishchevoda Barretta u naseleniya Vostochnoi Sibiri. Terapevticheskii arkhiv. 2013;85(1):62-65.
      14. Tsukanov V.V., Tret'yakova O.V., Amel'chugova O.S., Kasparov E.V., Rodina D.V., Vasyutin A.V., Butorin N.N., Tonkikh Yu.L. Rasprostranennost' atroficheskogo gastrita tela zheludka u naseleniya g. Krasnoyarska starshe 45 let. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii – The Russian Journal of Gastroenterology, Hepatology, Coloproctology. – 2012. – № 4. – С. 27-31.
      15. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process – First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Research. 1992;52(24):6735–6740.
      16. Polk D.B., Peek R.M.Jr. Helicobacter pylori: gastric cancer and beyond. Nature Reviews Cancer. 2010;10(6):403–414.
      17. Thiel A., Ristimaki A. Gastric cancer: basic aspects. Helicobacter. 2012;17(1):26–29.
      18. Dicksved J., Lindberg M., Rosenquist M., Enroth H., Jansson J.K., Engstrand L. Molecular characterization of the stomach microbiota in patients with gastric cancer and in controls. Journal of Medical Microbiology 2009. 58(4):509–516.
      19. Eun C.S., Kim B.K., Han D.S., Kim S.Y., Kim K.M., Choi B.Y., Song K.S., Kim Y.S., Kim J.F. Differences in gastric mucosal microbiota profiling in patients with chronic gastritis, intestinal metaplasia, and gastric cancer using pyrosequencing methods. Helicobacter. 2014;19(6):407–416.
      20. Yang I., Woltemate S., Piazuelo M.B., Suerbaum S. Different gastric microbiota compositions in two human populations with high and low gastric cancer risk in Colombia. Sci. Rep. 2016;6. – P. 18594.
      21. Dias-Jácome E., Libânio D., Borges-Canha M., Galaghar A., Pimentel-Nunes P. Gastric microbiota and carcinogenesis: the role of non-Helicobacter pyloribacteria – A systematic review. Rev. Esp. Enferm. Dig. 2016;108(9):530-540.
      22. Sugano K., Tack J., Kuipers E. J., Graham D.Y., El-Omar E.M.., Miura S., Haruma K.,Asaka M. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):353-1367.
      23. Malfertheiner P., Megraud F., O’Morain C.A., Gisbert J.P., Kuipers E.J., Axon A.T., Bazzoli, Gasbarrini A., Atherton J., Graham D.Y., Hunt R., Moayyedi P., Rokkas T.,Rugge M., Selgrad M., Suerbaum S., Sugano K., El-Omar E.M. Management of Helicobacter pylori infection-the Maastricht V. Florence Consensus Report. Gut. 2017;66(1):6-30.
      24. Minemura M., Shimizu Y. Gut microbiota and liver diseases. World J Gastroenterol. 2015;21(6):1691-1702.


    Full text is published :
    Tsukanov V.V., Kasparov E.V., Vasyutin A.V., Tonkih Yu.L. THE ROLE OF MICROBIOTA IN THE DEVELOPMENT OF GASTRIC PATHOLOGY. Experimental and Clinical Gastroenterology Journal. 2017;148(12):47-50
    Read & Download full text

    1. Far Eastern state medical University (Khabarovsk, Russian Federation)

    Abstract: The problem of extragastroduodenal manifestations of Helicobacter pylori infection has been studied for more than 20 years. The significance of Helicobacter pyloriin the development of idiopathic thrombocytopenic purpura, iron deficiency anemia and B 12-deficiency anemia, atherosclerosis, obesity, bronchial asthma, Alzheimer’s disease, Parkinson’s disease was reflected in the V Maastricht Consensus. The review presents the latest data on the association of Helicobacter pylori with cardiovascular, neurological, hematological, dermatological diseases, as well as with the development of diabetes mellitus and metabolic syndrome.

      1. Malfertheiner P., Megraud F., O’Morain C.A. et al. Management of Helicobacter pylori infection – the Maastricht V. Florence Consensus Report. Gut. 2017;66(1):6-30.
      2. Burns M., Muthupalani S., Ge Zh. et al. Helicobacter pylori infection induces anemia, depletes serum iron storage, and alters local iron-related and adult brain gene expression in male INS-GAS mice. PLoS One. 2015;10(11):e0142630. doi:10.1371/journal.pone.0142630.
      3. Emiralioglu N., Yenicesu I., Sari S. et al. An insight into the relationships between prohepcidin, iron deficiency anemia, and interleukin-6 values in pediatric Helicobacter pylori gastritis. European Journal of Pediatrics. 2015;174(7):903-910.
      4. Hwang J.J., Lee D.H., Yoon H. et al The effects of Helicobacter pylori eradication therapy for chronic idiopathic thrombocytopenic purpura. Gut and Liver. 2016;10(3):356-361.
      5. Amiri M. Impact of helicobacter pylori eradication therapy on platelet counts in patients with chronic idiopathic thrombocytopenic purpura. Global Journal of Health Science. 2005;8(7):35–40.
      6. Kim H., Lee W.S., Lee K.H. et al. Efficacy of Helicobacter pylori eradication for the 1 line treatment of immune thrombocytopenia patients with moderate thrombocytopenia. Annals of Hematology. 2015;94(5):739–746.
      7. Sun J., Rangan P., Bhat S.S., Liu L. A meta-analysis of the association between Helicobacter pylori infection and risk of coronary heart disease from published prospective studies. Helicobacter. 2016;21(1):11–23.
      8. Matusiak, A., Chałubiński M., Broncel M. et al. Putative consequences of exposure to Helicobacter pyloriinfection in patients with coronary heart disease in terms of humoral immune response and inflammation. Archives of Medical Science. 2016;12(1):45–54.
      9. Niccoli G., Roberto M., D’Amario D. et al. Cytotoxin-associated gene antigen-positive strains of Helicobacter pyloriand recurring acute coronary syndromes. European Heart Journal: Acute Cardiovascular Care. 2015;460(3):721–726.
      10. Lin Y., Obata Y., Kikuchi S. Helicobacter pylori infection and risk of death from cardiovascular disease among the japanese population: a nested case-control study within the JACC study. Journal of Atherosclerosis and Thrombosis. 2015;22(11):1207–1213.
      11. Xu Y., , Wang Q., Liu Y. et al. Association between Helicobacter pylori infection and carotid atherosclerosis in patients with vascular dementia. Journal of the Neurological Sciences. 2016;362:73–77.
      12. Sarıcı S.U., Gursel O., Kurekci E., Kesik V. Anticardiolipin antibodies in children with Helicobacter pylori infection. Helicobacter. 2015;20(6):418–421.
      13. Huang B., Chen Q. Xie et al. CagA-positive Helicobacter pylori strains enhanced coronary atherosclerosis by increasing serum OxLDL and HsCRP in patients with coronary heart disease. Digestive Diseases and Sciences. 2011;(56)1:109–114.
      14. Yan J., Yan J., She Q., Zhang Y. et al. The association between arrhythmia and Helicobacter pylori infection: a meta-analysis of case-control studies. International Journal of Environmental Research and Public Health. 2016;13(11). doi:10.3390/ijerph13111139.
      15. Bua X.L., Yaoa X.Q., Jiaoa S.S. et al. A study on the association between infectious burden and Alzheimer’s disease. European Journal of Neurology. 2015;22(12):1519–1525.
      16. Bua X. L., Bua X.L., Wang X., Xiang Y. The association between infectious burden and Parkinson’s disease: A case-control study. Parkinsonism and Related Disorders. 2015;21(8):877–881.
      17. Wang X.L., Bua X.L., Wang X., Xiang Y. Helicobacter pylori filtrate induces alzheimer-like Tau hyperphosphorylation by activating glycogen synthase kinase-3β. Journal of Alzheimer’s Disease. 2015;43(1):153–165.
      18. Rees K., Rees K., Stowe R., Patel S. et al. Helicobacter pylorieradication for Parkinson’s disease. Cochrane Database of Systematic Reviews. 2011(11).
      19. Jaruvongvanich V., Sanguankeo, S., Jaruvongvanich, Upala S. Association between Helicobacter pylori infection and multiple sclerosis: A systematic review and meta-analysis. Multiple Sclerosis and Related Disorders. 2016;7(3):92–97.
      20. Reibman J., Marmor M., Filner J. et al. Asthma is inversely associated with Helicobacter pylori status in an urban population. PLoS ONE. 2008;3(12) – e4060. doi: 10.1371/journal.pone.0004060.
      21. Chen Y. Inverse associations of Helicobacter pylori with asthma and allergy. Archives of Internal Medicine. 2007;167:821–827.
      22. Engler D. B., Reuterb S., Wijckc Y. et al. Effective treatment of allergic airway inflammation with Helicobacter pylori immunomodulators requires BATF3-dependent dendritic cells and IL-10. PNAS. 2014;111(32):11810–11815.
      23. Wang Y. C., Wang Y.C Lin T.Y., Shang S.T.,Chen H.J., Kao C.H., Wu C.C., Yang T.Y. Helicobacter pylori infection increases the risk of adult-onset asthma: a nationwide cohort study. European Journal of Clinical Microbiology & Infectious Diseases. 2017;36(9):1587–1594. doi:10.1007/s10096–017–2972–1.
      24. Sze M. A., Chen Y.R., Tam S. et al. The relationship between Helicobacter pylori seropositivity and COPD. Thorax. 2015. 70(10):923–929.
      25. Teke T.A., Akyön Y, Yalcin E. et al. Does Helicobacter pylori play a role in the pathogenesis of non-cystic fibrosis bronchiectasis? Pediatrics International. 2016;58(9):894–898.
      26. Kreuter M., Kreuter M., Kirsten D., Bahmer T. et al. Screening for Helicobacter pylori in idiopathic pulmonary fibrosis lung biopsies. Respiration. 2016:91:3–8.
      27. Nakashima S., Kakugawa T., Yura H. et al. Identification of Helicobacter pylori VacA in human lung and its effects on lung cells. Biochemical and Biophysical Research Communications. 2015;460(3):721–726.
      28. Lender N., Talley N.J., Enck P., Haag S., Zipfel S., Morrison M., Holtmann G.J. Review article: associations between Helicobacter pylori and obesity – an ecological study. Alimentary Pharmacology and Therapeutics. 2014;40(1):24–31.
      29. Lane J. A., Murray L.J., Harvey I.M. et al. Randomised clinical trial: Helicobacter pylori eradication is associated with a significantly increased body mass index in a placebo-controlled study. Alimentary Pharmacology & Therapeutics. 2011;33(8):922–929.
      30. Kasai C., Sugimoto K., Moritani I. Changes in plasma ghrelin and leptin levels in patients with peptic ulcer and gastritis following eradication of Helicobacter pylori infection. Gastroenterology. 2016;119:1–8.
      31. Chen L. W., Chien C. Y., Hsieh C. W. The associations between Helicobacter pylori infection, serum vitamin D, and metabolic syndrome. Medicine. 2016;95(18):1–6.
      32. Dai Y. N., Dai Y.N., Yu W.L., Zhu H. T. et al. Is Helicobacter pylori infection associated with glycemic control in diabetics? World Journal of Gastroenterology. 2015;21(17):5407–5416.
      33. Han X., Li Y., Wang J. et al. Helicobacter pylori infection is associated with type 2 diabetes among a middle- and old-age Chinese population. Diabetes. Metabolism Research and Reviews. 2016;32(1):95–101.
      34. Lebwohl B., Blaser M.J., Ludvigsson J.F. et al. Decreased risk of celiac disease in patients with Helicobacter pylori colonization. American Journal of Epidemiology. 2013;178(12):1721–1730.
      35. Dellon E.S., Peery A.F., Shaheen N.J. et al. Inverse association of esophageal eosinophilia with Helicobacter pylori based on analysis of a US pathology database. Gastroenterology. 2011;141(5):1586–1592.
      36. Rokkas T., Gisbert J.P., Niv Y., O’Morain C. The association between Helicobacter pylori infection and inflammatory bowel disease based on meta-analysis. United European Gastroenterology Journal. 2015;3(6):539–550.
      37. Kim T. J., Sinn D.H., Min Y.W.et al. A cohort study on Helicobacter pylori infection associated with nonalcoholic fatty liver disease. Journal of Gastroenterology. 2017;52(5). doi: 10.1007/s00535–017–1337-y.
      38. Chen C. X., Mao Y.S., Foster P. et al. Possible association between helicobacter pylori infection and non-alcoholic fatty liver disease. Applied Physiology, Nutrition, and Metabolism. 2017;42(3):295–301.
      39. Schulz C., Schütte K., Malfertheiner P. Does H. pylori eradication therapy benefit patients with hepatic encephalopathy? Systematic review. Journal of Clinical Gastroenterology. 2014;48(6):491–499.
      40. Shakouri A., Compalati E., Lang D.M., Khan D.A. Effectiveness of Helicobacter pylori eradication in chronic urticaria: evidence-based analysis using the Grading of Recommendations Assessment, Development, and Evaluation system. Current Opinion in Allergy & Clinical Immunology. 2010;10(4):362–369.
      41. Gu H., Li L., Gu M., G. Zhang G. Association between Helicobacter pylori infection and chronic urticaria: a meta-analysis. Gastroenterology Research and Practice. 2015:2015.
      42. Anwar W., Armstrong B.K., Correa P. et al. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7–14 June 1994. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. – 1994;61:1–241.
      43. Leontiadis G. I., Ford A.C., Moayyedi P. Helicobacter pylori infection BMJ Clinical Evidence. 2009:10.406–450.
      44. Zhao Y., Wang X., Wang Y. et al. Helicobacter pylori infection and colorectal carcinoma risk: A meta-analysis. Journal of Cancer Research and Therapeutics. 2016;12(1):15–18.
      45. Rabelo-Goncalves E. M., Sgardioli I.C., Lopes-Cendes I. et al. Improved detection of helicobacter pylori DNA in formalin-fixed paraffin-embedded (FFPE) tissue of patients with hepatocellular carcinoma using laser capture microdissection (LCM). Helicobacter. 2013;18:244–245.
      46. Guo Y., Liu W., Wu J. Helicobacter pylori infection and pancreatic cancer risk: A meta-analysis. Journal of Cancer Research and Therapeutics. 2016;32(3):229–232.


    Full text is published :
    Alekseenko S.A., Koltunov A.S., Koltunov S.S.EXTRAGASTROINTESTINAL MANIFESTATIONS OF HELICOBACTER PYLORI INFECTION. Experimental and Clinical Gastroenterology Journal. 2017;148(12):51-55
    Read & Download full text

    1. Kuban state medical University (Krasnodar, Russian Federation)
    2. Regional clinical hospital № 2 (Krasnodar, Russian Federation)

    Keywords: eosinophilic esophagitis, diagnostics

    Abstract: Eosinophilic esophagitis (EoE) is a rare diagnosed disease characterized by dysphagia symptoms. The lineament of the disease is eosinophilic infiltration of esophageal mucosa. A clinic case of EoE is presented and difficulties of differential diagnostics of EoE and gastro-esophageal reflux disease (GERD) are discussed. EoE is a disease that is similar to GERD in clinic features but different one in pathogenesis. It requires the principal new approach to treatment. Despite the clear differential-diagnostic criteria it should be keep in mind all clinical and histological constellations to exclude GERD, make right conclusion and choose the adequate tactics of treatment.

      1. Atkins D., Kramer R., Capocelli K., Lovell M., Furuta G.T. Eosinophilic esophagitis: the newest esophageal inflammatory disease. Nature Reviews Gastroenterology & Hepatology. 2009;6(5):267-278. doi:10.1038/nrgastro.2009.45
      2. Gonsalves N., Policarpio–Nicolas M., Zhang Q., Rao M.S., Hirano I. Histopathologic variability and endoscopic correlates in adults with eosinophilic esophagitis. Gastrointestinal Endoscopy. 2006;64(3):313-322.
      3. Dellon E.S., Gibbs W.B., Fritchie K.J., Rubinas T.C., Wilson L.A., Woosley J.T., Shaheen N.J. Clinical, endoscopic, and histologic findings distinguish eosinophilic esophagitis from gastroesophageal reflux disease. Clinical Gastroenterology and Hepatology. 2009;7(12):1305-1313.
      4. Liacouras C., Furuta G., Hirano I., Atkins D., Attwood S.E., Bonis P.A., Burks A.W., Chehade M., Collins M.H., Dellon E.S., Dohil R., Falk G.W., Gonsalves N., Gupta S.K., Katzka D.A., Lucendo A.J., Markowitz J.E., Noel R.J., Odze R.D., Putnam P.E., Richter J.E., Romero Y., Ruchelli E., Sampson H.A., Schoepfer A., Shaheen N.J., Sicherer S.H., Spechler S., Spergel J.M., Straumann A., Wershil B.K., Rothenberg M.E., Aceves S.S. Eosinophilic esophagitis: updated consensus recommendations for children and adults. The Journal of Allergy and Clinical Immunology. 2011;128(1):3-20.
      5. Ivashkin V.T., Baranskaya E.K., Kaibysheva V.O. et al. Klinicheskie rekomendatsii po diagnostike i lecheniyu eozinofil'nogo ezofagita. Moscow, 2013. 38 p.
      6. Langdon D. E. Congenital esophageal stenosis, corrugated ringed esophagus, and eosinophilic esophagitis. Am. J. Gastroenterol. 2000;95:2123-2124.
      7. Lim J., Gupta S., Fitzgerald J. et al. White specks in esophageal mucosa: a true endoscopic manifestation of severe eosinophilic esophagitis in children. J. Pediatr. Gastroenterol. Nutr. 2001;33:411.
      8. Krarup A., Villadsen G., Mejlgaard E., Olesen S.S., Drewes A.M.,Funch-Jensen. Acid hypersensitivity in patients with eosinophilic esophagitis. Scandinavian Journal of Gastroenterology. 2010;45(3):273-281.
      9. Markowitz J., Liacouras C. Eosinophilic esophagitis. Gastroenterology Clinics of North America. 2003;32(3):949-966.
      10. Foroutan M., Norouzi A., Molaei M., Mirbagheri S.A., Irvani S., Sadeghi A., Derakhshan F., Tavassoli S., Besharat S., Zali M. Eosinophilic esophagitis in patients with refractory gastroesophageal reflux disease. Digestive Diseases and Science. 2010;55(1):28-31.
      11. Landres R., Kuster G., Strum W. Eosinophilic esophagitis in a patient with vigorous achalasia. Gastroenterology. 1978;74:1298-301.
      12. Prasad G.A., Alexander J.A., Schleck C.D., Zinsmeister A.R., Smyrk T.C., Elias R.M., Locke G.R., Talley N.J. Epidemiology of eosinophilic esophagitis over three decades in Olmsted county, Minnesota. Clin. Gastroenterol. Hepatol. 2009;7(10):1055-1116.
      13. Straumann A., Spichtin H., Bernoulli R. Loosli J., Vögtlin J. Idiopathic eosinophilic esophagitis: a frequently overlooked disease with typical clinical aspects and discrete endoscopic findings (in German). Schweiz. Med. Wochenschr. 1994;Vol.124:1419-1429.
      14. Ahmad M., Soetikno R., Ahmed A. The differential diagnosis of eosinophilic esophagitis. Journal of Clinical Gastroenterology. 2000;30(3):242-244.
      15. Bohm M., Richter J., Kelsen S., Thomas R. Esophageal dilation: simple and effective treatment for adults with eosinophilic esophagitis and esophageal rings and narrowing. Diseses of the Esophagus. 2010;23(5):377-385.
      16. Furuta G. T. Eosinophilic esophagitis: Update on clinicopathological manifestations and pathophysiology. Curr. Opin. Gastroenterol. 2011;27(4):383-388.


    Full text is published:
    Serikova S.N., Korochanskaya N.V. DIFFICULTIES OF DIFFERENTIAL DIAGNOSTICS OF EOSINOPHILIC ESOPFAGITIS AND GASTRO-ESOPHAGEAL REFLUX DISEASE. Experimental and Clinical Gastroenterology Journal. 2017;148(12):56-59
    Read & Download full text